Cidara Therapeutics
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. The last earnings update was 17 days ago. More info.
Add to Portfolio Compare Print
- Cidara Therapeutics has significant price volatility in the past 3 months.
CDTX Share Price and Events
7 Day Returns
1 Year Returns
CDTX Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Cidara Therapeutics (CDTX) | -5% | -16.5% | -28.9% | -67.7% | -82.9% | - |
| US Biotechs | 0.3% | -1.4% | -4.9% | -4.9% | 3.6% | 11% |
| US Market | -1.4% | -3.9% | 0.2% | 1.6% | 33.2% | 38.2% |
1 Year Return vs Industry and Market
- CDTX underperformed the Biotechs industry which returned -4.9% over the past year.
- CDTX underperformed the Market in United States of America which returned 1.6% over the past year.
Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for Cidara Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $1.92.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Cidara Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Cidara Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $-2.58 |
| NasdaqGM:CDTX Share Price ** | NasdaqGM (2019-05-24) in USD | $1.92 |
| United States of America Biotechs Industry PE Ratio | Median Figure of 35 Publicly-Listed Biotechs Companies | 18.23x |
| United States of America Market PE Ratio | Median Figure of 3,084 Publicly-Listed Companies | 17.44x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Cidara Therapeutics.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGM:CDTX Share Price ÷ EPS (both in USD) = 1.92 ÷ -2.58 |
-0.75x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Cidara Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
- Cidara Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
Cidara Therapeutics's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -0.75x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts |
11.4%per year |
| United States of America Biotechs Industry PEG Ratio | Median Figure of 28 Publicly-Listed Biotechs Companies | 1.22x |
| United States of America Market PEG Ratio | Median Figure of 2,121 Publicly-Listed Companies | 1.51x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Cidara Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Cidara Therapeutics's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $1.65 |
| NasdaqGM:CDTX Share Price * | NasdaqGM (2019-05-24) in USD | $1.92 |
| United States of America Biotechs Industry PB Ratio | Median Figure of 416 Publicly-Listed Biotechs Companies | 3.17x |
| United States of America Market PB Ratio | Median Figure of 5,207 Publicly-Listed Companies | 1.8x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGM:CDTX Share Price ÷ Book Value per Share (both in USD) = 1.92 ÷ 1.65 |
1.17x |
* Primary Listing of Cidara Therapeutics.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Cidara Therapeutics is good value based on assets compared to the US Biotechs industry average.
Value checks
We assess Cidara Therapeutics's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Cidara Therapeutics has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Cidara Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
- Unable to compare Cidara Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
- Unable to compare Cidara Therapeutics's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGM:CDTX Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts | 11.4% |
| United States of America Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 22.6% |
| United States of America Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 17.7% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.7% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 52 | -20 | -32 | 2 |
| 2022-12-31 | 17 | -54 | -62 | 2 |
| 2021-12-31 | 0 | -77 | -78 | 3 |
| 2020-12-31 | 0 | -73 | -76 | 3 |
| 2019-12-31 | 0 | -74 | -68 | 3 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | -59 | -69 | |
| 2018-12-31 | -57 | -69 | |
| 2018-09-30 | -53 | -70 | |
| 2018-06-30 | -54 | -69 | |
| 2018-03-31 | -50 | -59 | |
| 2017-12-31 | -50 | -56 | |
| 2017-09-30 | -52 | -57 | |
| 2017-06-30 | -46 | -57 | |
| 2017-03-31 | -43 | -52 | |
| 2016-12-31 | -40 | -48 | |
| 2016-09-30 | -35 | -44 | |
| 2016-06-30 | -34 | -41 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
All data from Cidara Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | -0.58 | -0.33 | -0.71 | 3.00 |
| 2022-12-31 | -1.21 | -0.98 | -1.51 | 3.00 |
| 2021-12-31 | -1.58 | -1.04 | -2.06 | 4.00 |
| 2020-12-31 | -1.71 | -1.12 | -1.97 | 4.00 |
| 2019-12-31 | -2.05 | -1.69 | -2.32 | 4.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | -2.58 |
| 2018-12-31 | -2.76 |
| 2018-09-30 | -3.05 |
| 2018-06-30 | -3.40 |
| 2018-03-31 | -3.19 |
| 2017-12-31 | -3.18 |
| 2017-09-30 | -3.39 |
| 2017-06-30 | -3.55 |
| 2017-03-31 | -3.40 |
| 2016-12-31 | -3.32 |
| 2016-09-30 | -3.15 |
| 2016-06-30 | -2.94 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Cidara Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Cidara Therapeutics's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Cidara Therapeutics has a total score of 0/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Cidara Therapeutics performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Cidara Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Cidara Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Cidara Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Cidara Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | -69.16 | 14.27 | 48.61 | |
| 2018-12-31 | -69.35 | 14.14 | 49.14 | |
| 2018-09-30 | -70.43 | 13.82 | 46.33 | |
| 2018-06-30 | -69.07 | 13.46 | 44.21 | |
| 2018-03-31 | -59.08 | 13.35 | 45.78 | |
| 2017-12-31 | -55.73 | 12.90 | 42.82 | |
| 2017-09-30 | -56.69 | 12.71 | 43.90 | |
| 2017-06-30 | -56.66 | 13.23 | 43.47 | |
| 2017-03-31 | -51.77 | 13.20 | 38.75 | |
| 2016-12-31 | -48.17 | 12.74 | 35.70 | |
| 2016-09-30 | -43.64 | 12.06 | 31.95 | |
| 2016-06-30 | -40.59 | 10.89 | 29.99 | |
| 2016-03-31 | -35.25 | 9.74 | 25.73 | |
| 2015-12-31 | -32.19 | 8.84 | 23.48 | |
| 2015-09-30 | -26.97 | 7.65 | 19.39 | |
| 2015-06-30 | -21.12 | 6.54 | 14.61 | |
| 2015-03-31 | -17.92 | 4.82 | 11.37 | |
| 2014-12-31 | -11.89 | 3.31 | 6.71 | |
| 2014-09-30 | -7.65 | 2.19 | 3.47 | |
| 2013-12-31 | -1.34 | 0.27 | 0.81 | |
| 2012-12-31 | -0.79 | 0.78 | 0.01 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Cidara Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Cidara Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Cidara Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Cidara Therapeutics's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Cidara Therapeutics has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Cidara Therapeutics's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Cidara Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
- Cidara Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Cidara Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 4.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Cidara Therapeutics Company Filings, last reported 1 month ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 43.86 | 12.22 | 57.41 |
| 2018-12-31 | 59.14 | 9.93 | 74.56 |
| 2018-09-30 | 69.93 | 9.92 | 88.27 |
| 2018-06-30 | 82.14 | 9.91 | 103.20 |
| 2018-03-31 | 50.92 | 9.89 | 66.19 |
| 2017-12-31 | 59.74 | 9.87 | 75.31 |
| 2017-09-30 | 50.57 | 9.85 | 64.15 |
| 2017-06-30 | 61.26 | 9.83 | 78.01 |
| 2017-03-31 | 75.99 | 9.81 | 90.09 |
| 2016-12-31 | 88.18 | 9.79 | 104.62 |
| 2016-09-30 | 73.92 | 0.00 | 79.31 |
| 2016-06-30 | 84.81 | 0.00 | 87.09 |
| 2016-03-31 | 95.08 | 0.00 | 96.66 |
| 2015-12-31 | 103.91 | 0.00 | 107.51 |
| 2015-09-30 | 112.63 | 0.00 | 114.42 |
| 2015-06-30 | 120.86 | 0.00 | 122.30 |
| 2015-03-31 | 56.94 | 0.00 | 58.12 |
| 2014-12-31 | 21.10 | 0.00 | 22.80 |
| 2014-09-30 | 25.57 | 0.00 | 25.57 |
| 2013-12-31 | -1.40 | 1.48 | 0.19 |
| 2012-12-31 | -0.07 | 0.00 | 0.00 |
- Cidara Therapeutics's level of debt (27.9%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (13% vs 27.9% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Cidara Therapeutics has less than a year of cash runway based on current free cash flow.
- Cidara Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 18.6% each year.
Financial health checks
We assess Cidara Therapeutics's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Cidara Therapeutics has a total score of 3/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Cidara Therapeutics's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Cidara Therapeutics
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Cidara Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Cidara Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 19 Stocks | 2.4% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2007 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.5% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.8% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | 0.00 | 1.00 |
| 2020-12-31 | 0.00 | 1.00 |
| 2019-12-31 | 0.00 | 1.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Cidara Therapeutics has not reported any payouts.
- Unable to verify if Cidara Therapeutics's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Cidara Therapeutics's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Cidara Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Cidara Therapeutics has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | $1,363,737 |
| AGE | 63 |
| TENURE AS CEO | 5.3 years |
CEO Bio
Dr. Jeffrey L. Stein, also known as Jeff, Ph.D., has been the Chief Executive Officer, President and Executive Director of Cidara Therapeutics, Inc. since January 2014. Dr. Stein was Principal Financial Officer at Cidara Therapeutics, Inc. Dr. Stein serves as Principal Scientist of Verenium Corporation. He is Scientific Advisor of Spero Therapeutics, Inc. Dr. Stein served as Senior Vice President of Educational Strategy at MedCases, LLC. Dr. Stein served as a Principal Scientist of BASF Enzymes LLC. He also serves as a Faculty Research Associate at UC San Diego's Center for Marine Biotechnology and Biomedicine and in the Marine Biology Research Division of Scripps Institution of Oceanography. Dr. Stein was also founding Chairman and President of the Antibiotics Working Group. Dr. Stein served as the President and Chief Executive Officer of Trius Therapeutics Inc. since February 2007. From 2005 to 2010, he was a Venture Partner at Sofinnova Ventures, Inc. He joined the Sofinnova Ventures, Inc. in May 2005 as a Kauffman Fellow at the Sofinnova Ventures till 2007 and was a part of the life science team. He works with Sofinnova's life science investment team to identify San Diego-based investment opportunities in the area of biopharmaceutical clinical development and advises the firm's life science portfolio companies on clinical and business matters. He has held senior scientific and management positions in the biopharmaceutical industry for the past 20 years. From 1999 to 2005, Dr. Stein was the Founder & Chief Scientific Officer of Quorex Pharmaceuticals, Inc. from 1999 until its acquisition by Pfizer Pharmaceuticals, Inc. in 2005 and also served as its Executive Vice President. He served as a Principal Scientist and head of the anti-infectives discovery team at Diversa Corporation. From 1995 to 1999, Dr. Stein was a scientist with the Diversa Corporation. From 1993 to 1995, he was a Principal Investigator at the Agouron Institute, where his laboratory developed techniques to clone and characterize microbial gene pathways. He serves on the Board of Rx3 Pharmaceuticals and Quorex. He has been a Director of IDEAYA Biosciences, Inc. since October 2015. He has been a Director of Paratek Pharmaceuticals, Inc. since October 30, 2014. He served as an Executive Director of Trius Therapeutics, Inc. since 2005. He served as a Director of Quorex Pharmaceuticals, Inc. He served as Director of Venture Development at University of California - San Diego. He was also founding Chairman and President of the Antibiotics Working Group. Dr. Stein has also served as Director of Venture Development at UC San Diego from 2005 to 2006. He is considered an authority on the cloning and expression of microbial gene pathways and is a frequent invited lecturer on this topic at research and governmental institutions worldwide. he was a past member of the National Research Counsel’s Task Group for the Limits of Organic Life in Planetary Systems, a member of the President’s Panel on National Ocean Exploration Strategy and a past member of the National Science Foundation’s Engineering Center Site Review Team. Among the various honors he has received is the Thomas Alva Edison Patent Award. Dr. Stein holds a Ph.D. in Biochemistry and Marine Biology from the University of California, San Diego. Dr. Stein conducted his postdoctoral research in bacterial genetics as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology. Dr. Stein obtained a B.S. in Marine Biology and an M.S. in Biology from California State University, Long Beach. He is Graduate Student Researcher Fellow at UCSD.
CEO Compensation
- Jeff's compensation has been consistent with company performance over the past year, both up more than 20%.
- Jeff's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Cidara Therapeutics management team in years:
- The tenure for the Cidara Therapeutics management team is about average.
Management Team
Jeff Stein
President
$1M
63
5.3 yrs
Paul Daruwala
COO & Chief Commercial Officer
$662K
49
1.3 yrs
Taylor Sandison
Chief Medical Officer
$678K
46
2.7 yrs
Kevin Forrest
Founder and Chief Strategy Officer
$613K
41
2.8 yrs
Jamie Levine
Chief Financial Officer
47
0.4 yrs
Brady Johnson
Principal Accounting Officer
0.8 yrs
Jessica Oien
General Counsel & Secretary
47
0.7 yrs
Ken Bartizal
Chief Development Officer
$335K
67
4.8 yrs
Jim Balkovec
Senior Vice President of Research
4.3 yrs
Neil Abdollahian
Chief Business Officer
$946K
45
2.8 yrs
Board of Directors Tenure
Average tenure and age of the Cidara Therapeutics board of directors in years:
- The tenure for the Cidara Therapeutics board of directors is about average.
Board of Directors
Scott Rocklage
Chairman of the Board
$113K
63
6.3 yrs
Jeff Stein
President
$1M
63
5.3 yrs
Dan Burgess
Independent Director
$99K
56
5.1 yrs
Ted Schroeder
Independent Director
$98K
63
5.1 yrs
Tim Franson
Director
$91K
66
4.2 yrs
Chrysa Mineo
Independent Director
$179K
53
1.2 yrs
David Gollaher
Director
$99K
68
0.7 yrs
Who owns this company?
Recent Insider Trading
- Cidara Therapeutics insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 09. Mar 19 | Sell | Paul Daruwala | Individual | 07. Mar 19 | 07. Mar 19 | -2,240 | $2.55 | $-5,714 | ||
| 09. Mar 19 | Sell | Neil Abdollahian | Individual | 08. Mar 19 | 08. Mar 19 | -2,300 | $2.44 | $-5,612 | ||
Management checks
We assess Cidara Therapeutics's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Cidara Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Read This Before Selling Cidara Therapeutics, Inc. (NASDAQ:CDTX) Shares
Cidara Therapeutics Insider Transactions Over The Last Year. … In the last twelve months, the biggest single purchase by an insider was when President Jeffrey Stein bought US$1.0m worth of shares at a price of US$4.70 per share. … That means that an insider was happy to buy shares at above the current price.
Simply Wall St - – Full articleWhat Kind Of Shareholder Owns Most Cidara Therapeutics, Inc. (NASDAQ:CDTX) Stock?
Generally speaking, as a company grows, institutions will increase their ownership. … Conversely, insiders often decrease their ownership over time. … We also tend to see lower insider ownership in companies that were previously publicly owned.
Simply Wall St - – Full articleHave Insiders Been Buying Cidara Therapeutics Inc (NASDAQ:CDTX) Shares?
However, rules govern insider transactions, including certain disclosures. … Cidara Therapeutics Insider Transactions Over The Last Year. … In the last twelve months, the biggest single purchase by an insider was when CEO, President Jeffrey Stein bought US$1.0m worth of shares at a price of US$4.70 per share.
Simply Wall St - – Full articleWhat Kind Of Shareholders Own Cidara Therapeutics Inc (NASDAQ:CDTX)?
The big shareholder groups in Cidara Therapeutics Inc (NASDAQ:CDTX) have power over the company. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Cidara Therapeutics is a smaller company with a market capitalization of US$110m, so it may still be flying under the radar of many institutional investors.
Simply Wall St - – Full articleCidara Therapeutics Inc (NASDAQ:CDTX): Risks You Need To Consider Before Buying
If you're interested in Cidara Therapeutics Inc (NASDAQ:CDTX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.
Simply Wall St - – Full articleBreakeven On The Horizon For Cidara Therapeutics Inc (NASDAQ:CDTX)
Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. … With the latest financial year loss of -US$55.73m and a trailing-twelve month of -US$59.08m, the US$148.08m market-cap amplifies its loss by moving further away from its breakeven target … Many investors are wondering the rate at which CDTX will turn a profit, with the big question being “when will the company breakeven?”
Simply Wall St - – Full articleIs It The Right Time To Buy Cidara Therapeutics Inc (CDTX)?
I find that CDTX’s ratio of 2.6x is trading slightly below its industry peers’ ratio of 3.7x, which means if you buy CDTX today, you’d be paying a relatively fair price for it. … Currently, CDTX appears to be trading around its fair value, but given the uncertainty from negative returns in the future, this could be the right time to de-risk your portfolio. … The stock appears to be trading at fair value, which means there’s less benefit from mispricing.
Simply Wall St - – Full articleCompany Info
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. Its lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. The company, through its Cloudbreak platform, focuses on the treatment of infectious diseases that include viral and bacterial infections. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Details
| Name: | Cidara Therapeutics, Inc. |
| CDTX | |
| Exchange: | NasdaqGM |
| Founded: | 2012 |
| $51,152,353 | |
| 26,641,851 | |
| Website: | http://www.cidara.com |
| Address: |
Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101, San Diego, California, 92121, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGM | CDTX | Common Shares | Nasdaq Global Market | US | USD | 15. Apr 2015 | |
| DB | 20D | Common Shares | Deutsche Boerse AG | DE | EUR | 15. Apr 2015 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/26 00:44 |
| End of day share price update: | 2019/05/24 00:00 |
| Last estimates confirmation: | 2019/05/18 |
| Last earnings filing: | 2019/05/09 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
